Clik here to view.
Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2017
Monday, June 26th 2017 at 8:30pm UTC NEW YORK–(BUSINESS WIRE)– Regulatory News: Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) Shareholders’ General Meeting (Alternext: ALCLS – Nasdaq: CLLS) was held on...
View ArticleClik here to view.
Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with...
Tuesday, June 27th 2017 at 12:15pm UTC JERUSALEM & BURNABY, British Columbia–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Xenon Pharmaceuticals Inc. (Nasdaq:...
View ArticleClik here to view.
Modern Family Star Eric Stonestreet Challenges Americans to Support the...
Wednesday, June 28th 2017 at 10:59am UTC Dallas Cowboys quarterback Dak Prescott and actress/author Tia Mowry join Eric Stonestreet, Bristol-Myers Squibb and 30 cancer advocacy groups for the third...
View ArticleClik here to view.
NOVALIQ afianza su equipo directivo con el nombramiento de Gabriela Burian,...
Wednesday, June 28th 2017 at 12:11pm UTC Contacts Contacto:NOVALIQ GmbHFor US:Michael O’Rourke + 1 813 323 1438Strategic Consultantmrourke@novaliq.comoFor EU/Asia:Heidrun Kirsch + 49 6221 50259 243VP...
View ArticleClik here to view.
First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical...
Tuesday, June 27th 2017 at 8:30pm UTC UCART123 is the First U.S. Gene Edited, Off-the-Shelf CAR T-Cell Program NEW YORK–(BUSINESS WIRE)– Regulatory News: Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a...
View ArticleClik here to view.
NOVALIQ renforce son équipe de haute direction avec la nomination de Gabriela...
Tuesday, June 27th 2017 at 10:04pm UTC HEIDELBERG, Allemagne–(BUSINESS WIRE)– NOVALIQ GmbH, une société pharmaceutique spécialisée propriétaire d’une plateforme disruptive d’administration...
View ArticleClik here to view.
Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License...
Thursday, June 29th 2017 at 12:30pm UTC INCHEON, South Korea & JERUSALEM–(BUSINESS WIRE)– Celltrion, Inc., a global biopharmaceutical company, and Teva Pharmaceutical Industries Ltd. (NYSE and...
View ArticleClik here to view.
Acorda Submits New Drug Application to U.S. Food and Drug Administration for...
Thursday, June 29th 2017 at 8:01pm UTC ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (NASDAQ: ACOR) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)...
View ArticleClik here to view.
Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors
Wednesday, June 28th 2017 at 8:30pm UTC NEW YORK–(BUSINESS WIRE)– Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company...
View ArticleClik here to view.
Enzo Biochem Reports Delaware Court Ruling
Thursday, June 29th 2017 at 12:00pm UTC NEW YORK–(BUSINESS WIRE)– Enzo Biochem Inc. (NYSE:ENZ) reported today that a federal judge for the U.S. District Court for the District of Delaware has entered...
View ArticleClik here to view.
Chugai Deploys RaveX to Modernize Post-Marketing Surveillance
Thursday, June 29th 2017 at 11:30pm UTC Tokyo-based Pharmaceutical Company Expands Use of Medidata’s Unified Technology Platform to Simplify Study Navigation, Improve Data Quality and Speed Data Entry...
View ArticleClik here to view.
BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory...
Friday, June 30th 2017 at 11:30am UTC NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin) as monotherapy for...
View ArticleClik here to view.
Neil Goldsmith Stepping Down as CEO and Board Member of Evolva
Thursday, July 6th 2017 at 8:15pm UTC REINACH, Switzerland–(BUSINESS WIRE)– Evolva (SIX: EVE) today announces the departure of CEO Neil Goldsmith and his succession by the current Chief Operating...
View ArticleClik here to view.
SmartZyme Adds Two Drug Development Veterans to Broaden and Strengthen...
Wednesday, July 5th 2017 at 2:00pm UTC Mark Leavitt, Ph.D. Appointed Vice President of R&D and Chief Technology Officer Christopher R. Shepard, Ph.D. Appointed Senior Vice President of Business...
View ArticleClik here to view.
Cellectis: Calyxt Announces Proposed Initial Public Offering of $100.0 Million
Monday, July 10th 2017 at 11:06am UTC ST. PAUL, Minn. & NEW YORK–(BUSINESS WIRE)– Regulatory News: This Smart News Release features multimedia. View the full release here:...
View ArticleClik here to view.
Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in...
Monday, July 10th 2017 at 12:00pm UTC – First phase 3 trial in a global clinical development program to explore the combination of these agents – – Exelixis, Bristol-Myers Squibb and Ipsen to co-fund...
View ArticleClik here to view.
Cytovia Inc, Immune Pharmaceuticals’ Oncology Subsidiary, Enters into a...
Tuesday, July 11th 2017 at 5:45pm UTC NEW YORK–(BUSINESS WIRE)– Cytovia Inc. (“Cytovia”) the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (« Immune ») announced today that it has...
View ArticleClik here to view.
Teva to Report Second Quarter 2017 Financial Results on August 3, 2017
Tuesday, July 11th 2017 at 2:00pm UTC JERUSALEM–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its second quarter 2017 financial results on...
View ArticleClik here to view.
Kadmon Announces Interim Phase 2 Data of KD025 in Chronic Graft-Versus-Host...
Tuesday, July 11th 2017 at 12:00pm UTC Overall Response Rate of 71%, with a Favorable Safety Profile Findings to be Presented and Webcast Today at 8:45 a.m. ET at Kadmon’s Research and Development...
View ArticleClik here to view.
Genoox Raises $6 Million in Funding to Fuel Expansion Into U.S. Healthcare...
Tuesday, July 11th 2017 at 1:30pm UTC The genomic analysis company makes it easier for doctors, clinicians and researchers to quickly analyze genetic data and make informed decisions to improve...
View Article